Generation Bio to Present at the 43rd Annual Cowen Healthcare Conference 

Rhea-AI Summary

Generation Bio (Nasdaq:GBIO), a biotechnology firm focused on genetic medicines, announced that Geoff McDonough, M.D., the president and CEO, will speak at the Gene Therapy panel during the 43rd Annual Cowen Healthcare Conference. This event is scheduled for March 6th at 10:30 a.m. EST in Boston, MA. A live webcast will be accessible on the company's investor website, with a replay available for 30 days post-event.

Generation Bio aims to provide innovative treatments for rare and prevalent diseases using its proprietary non-viral genetic medicine platform. This includes closed-ended DNA (ceDNA) technology and cell-targeted lipid nanoparticle delivery systems.

CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in the Gene Therapy panel discussion at the 43^rd Annual Cowen Healthcare Conference on Monday, March 6^th at 10:30 a.m. EST in Boston, MA.

A live webcast of the panel will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.

About Generation Bio 
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific cell types, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world. 
For more information, please visit www.generationbio.com. 

Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638

FAQ

When is Generation Bio's presentation at the Cowen Healthcare Conference?

Generation Bio's presentation is on March 6th at 10:30 a.m. EST.

Where can I watch the Generation Bio panel discussion live?

The panel discussion can be watched live on Generation Bio's investor website.

What is the focus of Generation Bio's genetic medicine platform?

Generation Bio's platform focuses on providing durable, redosable treatments for rare and prevalent diseases.

What innovative technology does Generation Bio use in its treatments?

Generation Bio uses closed-ended DNA (ceDNA) and a unique cell-targeted lipid nanoparticle delivery system.

What is the significance of the event for Generation Bio?

The event highlights Generation Bio's advancements in genetic medicine and its commitment to addressing various diseases.